Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
the serotonin transporter gene gene	mechanism	the serotonin transporter gene loci	1	0	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
tcf4 gene	mechanism	tcf4 gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
casein	mechanism	gluten	2	0	26418822|26148018	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.|PMID:26148018; Original text:The mean approach withdrawal problem composite score was significantly higher before supplementation than after, both in the placebo and in the gluten-casein group.
interleukin-6	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	il-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
kiaa0319l	mechanism	tdo2	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism	kiaa0319l	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism	tdo2	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
methylene tetrahydrofolate reductase	mechanism	mthfr	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
baz1b	mechanism	gtf2ird1	1	0	30008175	PMID:30008175; Original text:However, we report on two nominally significant SNPs in two genes that have been implicated in the cognitive and social phenotypes of Williams syndrome, BAZ1B and GTF2IRD1.
foxp3	mechanism	toll-like receptor-4	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism	foxp3	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism	toll-like receptor-4	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
serotonin transporter	mechanism	sert	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
fra(x)	mechanism	fra(x) males	1	0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
foxp3+domain-3+	mechanism	il-17+domain-3+	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
ifn-γ+domain-3+	mechanism	il-17+domain-3+	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
foxp3+domain-3+	mechanism	ifn-γ+domain-3+	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
activator protein 1	mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism	ap-1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism	nf-κb	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nf-κb	mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism	nf-κb	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
casein-	mechanism	gluten-	1	0	15106205	PMID:15106205; Original text:However, the fourth outcome, reduction in autistic traits, reported a significant beneficial treatment effect for the combined gluten- and casein- free diet.
the	mechanism	the serotonin transporter gene polymorphisms	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
s allele	mechanism	serotonin transporter genelpr	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
gws	mechanism	gws loci	1	0	28540026	PMID:28540026; Original text:Previous ASD the past decade genome-wide association studies have identified genome-wide significant (GWS) risk loci; however, these studies were of only of low statistical power to identify GWS loci at the lower effect sizes (odds ratio (odds ratio) <1.15).
oxytocin	mechanism	vasopressin	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
blood	mechanism	brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
interleukin)-1beta	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-8	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-8	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	interleukin)-1beta	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin)-1beta	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
monocyte chemotactic protein-1	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
zonulin	mechanism	zonulin peptide family	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
2d6	mechanism	5-httlpr gene	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism	cytochrome p450 2c19	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism	maoa	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism	cytochrome p450 2c19	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism	maoa	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
cytochrome p450 2c19	mechanism	maoa	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
basic fibroblast growth factor	mechanism	vascular endothelial growth factor	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism	nerve growth factor	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism	vascular endothelial growth factor	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
folate	mechanism	folate receptor alpha	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
epidermal growth factor	mechanism	il-13	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
serotonin	mechanism	serotonin receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
drd3 ser9gly	mechanism	slc6a4 5-httlpr polymorphism	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
high-density lipoprotein cholesterol	mechanism	low-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
fmr1 promoter	mechanism	mglur5	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
fmr1 promoter	mechanism	gabab	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
gabab	mechanism	mglur5	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
eotaxin	mechanism	monocyte chemoattractant protein-1	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
corticotropin-releasing factor	mechanism	neurotensin	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
casein	mechanism	gluten-	1	0	19917211	PMID:19917211; Original text:We also show highly significant decreases after introducing a gluten- and casein-free diet with a duration of more than 1 year.
dgcr6 genes	mechanism	prodh	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
blood	mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	blood neurotrophin-3	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	brain-derived neurotrophic factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	brain-derived neurotrophic factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
ferritin	mechanism	hemoglobin	1	0	17352947	PMID:17352947; Original text:Mean ferritin increased significantly (16 microg/L to 29 microg/L), as did mean corpuscular volume and hemoglobin, suggesting that low ferritin in this patient group resulted from insufficient iron intake.
insulin	mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism	hemoglobin a1c	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
plasma	mechanism	transferrin	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
plasma	mechanism	plasma superoxide dismutase	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
plasma superoxide dismutase	mechanism	transferrin	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
en2 gene	mechanism	wnt2 gene	1	0	22522212	PMID:22522212; Original text:Furthermore, we detected an interaction effect on age of first phrase between a SNP rs2228946 in the WNT2 gene and another SNP rs6460013 in the EN2 gene (p = 0.0012).
